An update from Haleon PLC ( (GB:HLN) ) is now available.
Haleon PLC announced the purchase of 828,379 ordinary shares for cancellation as part of its share buyback program. This transaction affects the company’s share capital, reducing the number of ordinary shares with voting rights to 9,033,248,207. The buyback program is part of Haleon’s strategy to manage its capital structure and potentially enhance shareholder value.
More about Haleon PLC
Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health with humanity. The company offers products across five major categories: Oral Health, Pain Relief, Respiratory Health, Digestive Health, and Vitamins, Minerals and Supplements. Its renowned brands include Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax, and Centrum, which are known for their trusted science and innovation.
YTD Price Performance: 3.87%
Average Trading Volume: 27,798,713
Technical Sentiment Signal: Sell
Current Market Cap: £35.35B
Learn more about HLN stock on TipRanks’ Stock Analysis page.